Friday, March 22, 2013

• Biogen’s Revolutionary Multiple Sclerosis Treatment Clears First Hurdleat Motley Fool (Fri, Mar 22)

Thursday, March 21, 2013

• EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSISThomson Reuters ONE (Thu, Mar 21)
• Early versus Delayed Treatment with Laquinimod Demonstrated Significant Reduction in Risk of Disability Progression – Results of Three-Year ALLEGRO Study in Relapsing-Remitting Multiple SclerosisBusiness Wire (Thu, Mar 21)

Wednesday, March 20, 2013

• This Spring's Allergy Season Will Be The Worst and Longest Everat Forbes (Wed, Mar 20)
• 4 Healthcare Stock Stories Prescribed for Investorsat Wall St. Cheat Sheet (Wed, Mar 20)
• 2 Biopharmaceuticals With Huge Upside Potentialat Motley Fool (Wed, Mar 20)
• New Data Show Azilect® (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinson’s When Added to Sub-Optimally Controlled Patients on Dopamine Agonist TherapyBusiness Wire (Wed, Mar 20)

Tuesday, March 19, 2013

• New Data on Biogen/Elan's TysabriZacks (Tue, Mar 19)
• Patients’ Generic-Drug Lawsuits Questioned by High Courtat Bloomberg (Tue, Mar 19)
• What's the Deal With Abbott Labs?at Motley Fool (Tue, Mar 19)

Monday, March 18, 2013

• Identifying Pipelines in Medical Devices: An Expert Equity Analyst Shares His Take on R&D in the Healthcare Industry and Shares Some of his Top Stock PicksWall Street Transcript (Mon, Mar 18)
• Generic drug makers fall after Wells analyst downgrades sectorat theflyonthewall.com (Mon, Mar 18)
• Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA)at TheStreet (Mon, Mar 18)
• Analysts' Actions: BTU HLS HPQ ODP TEVATheStreet (Mon, Mar 18)

Friday, March 15, 2013

• 3 Stocks Pushing The Health Care Sector Lowerat TheStreet (Fri, Mar 15)
• Actavis Profits Decrease As Acquisition Takes Tollat Motley Fool (Fri, Mar 15)

Thursday, March 14, 2013

• Picking Up the Pieces of Shattered Spectrumat Motley Fool (Thu, Mar 14)
• Does Teva's Dividend Have Room to Soar?at Motley Fool (Thu, Mar 14)
• Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual MeetingBusiness Wire (Thu, Mar 14)

Wednesday, March 13, 2013

• Spectrum Pharma Stock Plunges After Guidance Whackedat Investor's Business Daily (Wed, Mar 13)
• Down 35%! This Is a Biotech Trainwreckat Motley Fool (Wed, Mar 13)
• Clay Walker, Country Music Star And Relapsing-Remitting Multiple Sclerosis Patient Urges Others To "Stick With It"PR Newswire (Wed, Mar 13)

Tuesday, March 12, 2013

• Spectrum plunges after slashing Fusilev sales viewAP (Tue, Mar 12)
• [video] You Tweet it, We Trade it!at CNBC (Tue, Mar 12)
• Pain Is Pfizer’s Gainat Motley Fool (Tue, Mar 12)

Add TEVA News to My Yahoo!